Steve Engle is CEO of Averigon Consulting, an advisory firm to the life science industry. Previously, Mr. Engle was Chairman and CEO of XOMA, a developer of antibody therapeutics for inflammatory, metabolic and other diseases and which had partnerships with multiple pharmaceutical companies. Prior to that, he was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA.
Mr. Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a device company and a management consultant at Strategic Decisions Group and SRI International. Mr. Engle is a board member of Anthera Pharmaceuticals, AROA Biosurgery and Prescient Therapeutics. He is a former board member of BIO, Baybio, BIOCOM and the Lupus Foundation of America. Mr. Engle holds a B.S. and an M.S. in electrical engineering with a focus in biomedical engineering from the University of Texas at Austin.